Amgen AMGN announced that the FDA has approved its KRAS inhibitor, Lumakras (sotorasib), in combination with its anti-EGFR antibody, Vectibix (panitumumab), for treating KRAS G12C-mutated ...

The US regulator has cleared Lumakras (sotorasib) in combination with Amgen's anti-EGFR antibody Vectibix (panitumumab) for adults with KRAS G12C-mutated metastatic colorectal cancer (CRC ...

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Quantbot Technologies LP boosted its holdings in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 219.5% during the fourth ...

At the same time, one of the latest milestones in Amgen's oncology franchise was the FDA approval of the combination of Lumakras and Vectibix on January 17 for the treatment of certain patients ...

The approval is backed by Amgen’s (AMGN) CodeBreaK 300 trial, in which patients on sotorasib 960 mg/panitumumab recorded over ...

Amgen (NASDAQ:AMGN – Get Free Report) was upgraded by research analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a research note issued on Saturday. A number of other research ...

Amgen's recent affirmation of a $2.38 per share dividend for Q2 2025 could reflect investor confidence and perhaps aided in boosting its shares by 12% over the last quarter. The company's ...

Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals ...